ABCG2 and non-small cell lung carcinoma: Our findings indicate that while ABCP demonstrated superior efficacy in aggressive NSCLC subtypes, specifically in patients with liver metastases, brain metastases, and EGFR mutations, this advantage was accompanied by a higher toxicity burden.